On August 19, 2009, Cerus Corporation (the "Company") announced that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with the Company's INTERCEPT Blood System. A copy of the Company's press release, entitled "Cerus' INTERCEPT Blood System for Platelets Receives Swiss Approval," is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

(d) Exhibits

Exhibit
Number       Description
 99.1        Press Release, dated August 19, 2009, entitled "Cerus' INTERCEPT Blood
             System for Platelets Receives Swiss Approval."

1.